Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Henlius anti-PD-1 Approved to Launch in China for Small Cell Lung Cancer

publication date: Jan 18, 2023

Shanghai Henlius Biotech has been approved to launch its anti-PD-1 mAb in China as a first-line treatment for extensive stage small cell lung cancer. Hansizhuang (serplulimab injection), the first novel mAb developed by Henlius, is also the first anti-PD-1 approved as a first-line therapy for SCLC globally. The anti-PD-1 will be administered in combination with carboplatin and etoposide. Previously, Hansizhuang was approved in China as a first-line therapy in two non-small cell cancer indications: Microsatellite Instability-High (MSI-H) solid tumors and squamous non-small cell lung cancer. More details....

Stock Symbol: (HK: 2696)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital